Regeneron Pharmaceuticals (REGN) Short Interest Ratio & Short Volume $607.39 -7.40 (-1.20%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Regeneron Pharmaceuticals Short Interest DataRegeneron Pharmaceuticals (REGN) has a short interest of 2.89 million shares, representing 2.78% of the float (the number of shares available for trading by the public). This marks a 11.15% increase in short interest from the previous month. The short interest ratio (days to cover) is 2.7, indicating that it would take 2.7 days of the average trading volume of 790,807 shares to cover all short positions.Current Short Interest2,890,000 sharesPrevious Short Interest2,600,000 sharesChange Vs. Previous Month+11.15%Dollar Volume Sold Short$1.73 billionShort Interest Ratio2.7 Days to CoverLast Record DateApril 30, 2025Outstanding Shares107,965,000 sharesFloat Size104,060,000 sharesShort Percent of Float2.78%Today's Trading Volume325,087 sharesAverage Trading Volume790,807 sharesToday's Volume Vs. Average41% Short Selling Regeneron Pharmaceuticals? Sign up to receive the latest short interest report for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartREGN Short Interest Over TimeREGN Days to Cover Over TimeREGN Percentage of Float Shorted Over Time Regeneron Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20252,890,000 shares $1.73 billion +11.2%2.8%2.7 $598.76 4/15/20252,600,000 shares $1.45 billion -6.8%2.6%2.6 $557.91 3/31/20252,790,000 shares $1.77 billion -14.2%2.8%2.8 $634.23 3/15/20253,250,000 shares $2.17 billion +26.5%3.2%3.5 $666.87 2/28/20252,570,000 shares $1.80 billion +16.8%2.5%2.8 $698.74 2/15/20252,200,000 shares $1.48 billion +0.5%2.2%2.5 $673.60 1/31/20252,190,000 shares $1.47 billion +3.3%N/A2.4 $672.98 1/15/20252,120,000 shares $1.49 billion +1.0%N/A2.4 $703.43 12/31/20242,100,000 shares $1.50 billion +11.7%N/A2.6 $712.33 12/15/20241,880,000 shares $1.37 billion +4.4%N/A2.2 $731.30 Get the Latest News and Ratings for REGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/30/20241,800,000 shares $1.35 billion +0.6%N/A2.3 $750.22 11/15/20241,790,000 shares $1.35 billion -3.2%N/A2.5 $756.81 10/31/20241,850,000 shares $1.55 billion +7.6%N/A2.9 $838.20 10/15/20241,720,000 shares $1.75 billion -0.6%N/A3 $1,016.53 9/30/20241,730,000 shares $1.82 billion -12.6%N/A3.3 $1,051.24 9/15/20241,980,000 shares $2.28 billion -5.7%N/A4.1 $1,153.35 8/31/20242,100,000 shares $2.49 billion -0.5%N/A4.6 $1,184.69 8/15/20242,110,000 shares $2.48 billion +5.0%N/A4.7 $1,175.33 7/31/20242,010,000 shares $2.17 billion +6.4%N/A4.6 $1,079.19 7/15/20241,890,000 shares $2.05 billion -7.4%N/A4.3 $1,082.11 6/30/20242,040,000 shares $2.14 billion +10.3%N/A4.5 $1,051.03 6/15/20241,850,000 shares $1.92 billion +5.7%N/A4.1 $1,036.52 5/31/20241,750,000 shares $1.72 billion +7.4%N/A4 $980.16 5/15/20241,630,000 shares $1.59 billion +3.8%N/A3.7 $978.21 4/30/20241,570,000 shares $1.40 billion +13.0%N/A3.4 $890.66 4/15/20241,390,000 shares $1.25 billion -2.1%N/A3 $898.56 3/31/20241,420,000 shares $1.37 billion +2.2%N/A3 $962.49 3/15/20241,390,000 shares $1.34 billion +2.2%N/A2.7 $964.47 2/29/20241,360,000 shares $1.31 billion -0.7%N/A2.4 $966.09 2/15/20241,370,000 shares $1.31 billion +9.6%N/A2.4 $954.73 1/31/20241,250,000 shares $1.18 billion +16.8%N/A2.2 $942.78 1/15/20241,070,000 shares $998.52 million +0.9%1.0%1.9 $933.20 12/31/20231,060,000 shares $930.99 million -13.1%1.0%2 $878.29 12/15/20231,220,000 shares $1.05 billion -0.8%1.2%2.4 $859.14 11/30/20231,230,000 shares $1.01 billion -12.1%1.2%2.7 $823.81 11/15/20231,400,000 shares $1.11 billion +6.9%1.3%3.3 $792.38 10/31/20231,310,000 shares $1.02 billion -4.4%1.3%3 $779.89 10/15/20231,370,000 shares $1.15 billion +16.1%1.3%3 $839.63 9/30/20231,180,000 shares $971.09 million -18.6%1.1%2.4 $822.96 9/15/20231,450,000 shares $1.19 billion -2.0%1.4%2.5 $823.40Think NVDA’s run was epic? You ain’t seen nothin’ yet (Ad)Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 8/31/20231,480,000 shares $1.22 billion +8.8%1.4%2.5 $826.49 8/15/20231,360,000 shares $1.10 billion +1.5%1.3%2.1 $805.91 7/31/20231,340,000 shares $994.16 million +5.5%1.3%2.1 $741.91 7/15/20231,270,000 shares $912.52 million +17.6%N/A2 $718.52 6/30/20231,080,000 shares $776.02 million -12.2%N/A1.8 $718.54 6/15/20231,230,000 shares $963.18 million +7.9%N/A2.2 $783.07 5/31/20231,140,000 shares $838.54 million -5.8%N/A2 $735.56 5/15/20231,210,000 shares $908.66 million +2.5%N/A2.1 $750.96 4/30/20231,180,000 shares $946.11 million -2.5%1.1%2 $801.79 4/15/20231,210,000 shares $1.00 billion -6.9%1.2%2 $829.33 3/31/20231,300,000 shares $1.07 billion +7.4%1.2%2 $821.67 3/15/20231,210,000 shares $919.96 million +0.8%1.2%1.9 $760.30 2/28/20231,200,000 shares $912.50 million -10.5%1.2%1.9 $760.42 2/15/20231,340,000 shares $1.01 billion -8.2%1.3%2.1 $752.40 1/31/20231,460,000 shares $1.11 billion +3.6%1.4%2.2 $758.47 1/15/20231,410,000 shares $1.02 billion -6.0%1.4%2.2 $722.13 12/30/20221,500,000 shares $1.08 billion +4.2%1.5%2.2 $721.49 12/15/20221,440,000 shares $1.05 billion -7.1%1.4%2.1 $731.27 11/30/20221,550,000 shares $1.17 billion -11.9%1.5%2.1 $751.70 11/15/20221,760,000 shares $1.28 billion -0.6%1.7%2.3 $728.73 10/31/20221,770,000 shares $1.33 billion -16.1%1.7%2.3 $748.75 10/15/20222,110,000 shares $1.55 billion -7.5%2.1%2.8 $736.06 9/30/20222,280,000 shares $1.57 billion -3.8%2.2%3.2 $688.87 9/15/20222,370,000 shares $1.67 billion -18.6%2.3%3.5 $705.85 8/31/20222,910,000 shares $1.69 billion -0.7%2.8%4.3 $581.06 8/15/20222,930,000 shares $1.88 billion -4.6%2.9%4.6 $643.29 7/31/20223,070,000 shares $1.79 billion +7.3%3.0%4.6 $581.69 7/15/20222,860,000 shares $1.74 billion +3.3%2.8%4.3 $607.54 6/30/20222,770,000 shares $1.64 billion +7.4%N/A4.1 $591.13 6/15/20222,580,000 shares $1.45 billion +23.4%N/A3.7 $561.19 5/31/20222,090,000 shares $1.39 billion -4.1%N/A3.1 $664.74 5/15/20222,180,000 shares $1.41 billion +0.9%N/A3.4 $645.52 4/30/20222,160,000 shares $1.42 billion +0.5%N/A3.2 $659.11 4/15/20222,150,000 shares $1.58 billion -2.3%2.1%3 $733.02 3/31/20222,200,000 shares $1.54 billion -8.0%2.1%3 $698.42 3/15/20222,390,000 shares $1.59 billion +6.7%2.3%3.3 $665.93 2/28/20222,240,000 shares $1.39 billion +4.7%2.2%3 $618.36 2/15/20222,140,000 shares $1.35 billion +19.6%2.1%2.8 $630.15 1/31/20221,790,000 shares $1.09 billion -1.7%1.7%2.4 $608.59 1/15/20221,820,000 shares $1.12 billion +11.0%1.8%2.4 $615.24 12/31/20211,640,000 shares $1.04 billion +7.2%1.6%2.2 $631.52 12/15/20211,530,000 shares $1.01 billion +3.4%1.5%1.9 $657.93 11/30/20211,480,000 shares $942.06 million -8.1%1.4%2 $636.53 11/15/20211,610,000 shares $1.04 billion -14.4%1.6%2.1 $647.73 10/29/20211,880,000 shares $1.20 billion +6.8%1.8%2.3 $639.94 10/15/20211,760,000 shares $973.70 million -2.2%1.7%2.2 $553.24 9/30/20211,800,000 shares $1.09 billion +14.7%1.8%2.4 $605.18 9/15/20211,570,000 shares $1.02 billion +15.4%1.5%2 $652.00 8/31/20211,360,000 shares $915.82 million -3.6%1.3%1.7 $673.40 8/13/20211,410,000 shares $880.95 million -11.3%1.4%1.8 $624.79Think NVDA’s run was epic? You ain’t seen nothin’ yet (Ad)Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 7/30/20211,590,000 shares $913.63 million -13.6%1.6%2.1 $574.61 7/15/20211,840,000 shares $1.08 billion +30.5%1.8%2.4 $589.32 6/30/20211,410,000 shares $787.54 million -26.6%1.4%1.8 $558.54 6/15/20211,920,000 shares $1.01 billion -9.0%1.9%2.4 $527.49 5/28/20212,110,000 shares $1.06 billion -5.4%2.1%2.6 $502.43 5/14/20212,230,000 shares $1.15 billion -4.7%2.2%2.6 $517.17 4/30/20212,340,000 shares $1.13 billion -14.9%2.3%2.5 $485.00 4/15/20212,750,000 shares $1.32 billion +24.4%2.7%2.8 $481.16 3/31/20212,210,000 shares $1.04 billion -16.9%2.2%2.1 $470.67 3/15/20212,660,000 shares $1.25 billion +14.7%2.6%2.6 $471.46 2/26/20212,320,000 shares $1.05 billion +10.0%2.3%2.2 $453.19 2/12/20212,110,000 shares $1.04 billion +8.8%2.1%2 $490.54 1/29/20211,940,000 shares $982.16 million -18.8%1.9%2 $506.27 1/15/20212,390,000 shares $1.24 billion +6.2%2.4%2.6 $517.91 12/31/20202,250,000 shares $1.08 billion +14.8%2.2%2.4 $478.30 12/15/20201,960,000 shares $980.74 million -8.0%1.9%1.9 $500.38 11/30/20202,130,000 shares $1.09 billion +6.0%2.1%2.2 $514.05 11/15/20202,010,000 shares $1.14 billion -7.4%2.0%2.1 $566.43 10/30/20202,170,000 shares $1.21 billion -6.9%2.1%2.4 $555.79 10/15/20202,330,000 shares $1.40 billion +13.7%2.3%2.7 $600.82 9/30/20202,050,000 shares $1.15 billion +28.1%2.0%2.4 $559.78 9/15/20201,600,000 shares $927.84 million +0.6%1.6%2.1 $579.90 8/31/20201,590,000 shares $985.69 million -0.6%1.6%2 $619.93 8/14/20201,600,000 shares $980.11 million -15.3%1.6%1.4 $612.57 7/31/20201,890,000 shares $1.19 billion -5.0%1.9%1.5 $632.07 7/15/20201,990,000 shares $1.28 billion -6.1%1.9%1.5 $641.23 6/30/20202,120,000 shares $1.32 billion -14.2%2.0%1.5 $623.65 6/15/20202,470,000 shares $1.46 billion +24.1%2.3%1.7 $590.57 5/29/20201,990,000 shares $1.22 billion +11.8%1.9%1.3 $612.81 REGN Short Interest - Frequently Asked Questions What is Regeneron Pharmaceuticals' current short interest? Short interest is the volume of Regeneron Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 2,890,000 shares of REGN short. 2.78% of Regeneron Pharmaceuticals' shares are currently sold short. Learn More on Regeneron Pharmaceuticals' current short interest. What is a good short interest ratio for Regeneron Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. REGN shares currently have a short interest ratio of 3.0. Learn More on Regeneron Pharmaceuticals's short interest ratio. Which institutional investors are shorting Regeneron Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Regeneron Pharmaceuticals: Jane Street Group LLC, Goldman Sachs Group Inc., Parallax Volatility Advisers L.P., Millennium Management LLC, Cubist Systematic Strategies LLC, Nomura Holdings Inc., Twin Tree Management LP, BNP Paribas Financial Markets, Eisler Capital Management Ltd., Jane Street Group LLC, Walleye Trading LLC, Walleye Capital LLC, Capital Fund Management S.A., Persistent Asset Partners Ltd, Arrowpoint Investment Partners Singapore Pte. Ltd., JPMorgan Chase & Co., Citigroup Inc., Readystate Asset Management LP, Allianz Asset Management GmbH, Covenant Asset Management LLC, SG Americas Securities LLC, and Shufro Rose & Co. LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Regeneron Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.78% of Regeneron Pharmaceuticals' floating shares are currently sold short. Is Regeneron Pharmaceuticals' short interest increasing or decreasing? Regeneron Pharmaceuticals saw a increase in short interest in April. As of April 30th, there was short interest totaling 2,890,000 shares, an increase of 11.2% from the previous total of 2,600,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Regeneron Pharmaceuticals' float size? Regeneron Pharmaceuticals currently has issued a total of 107,965,000 shares. Some of Regeneron Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Regeneron Pharmaceuticals currently has a public float of 104,060,000 shares. How does Regeneron Pharmaceuticals' short interest compare to its competitors? 2.78% of Regeneron Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Regeneron Pharmaceuticals: Amgen Inc. (2.72%), Gilead Sciences, Inc. (1.90%), Vertex Pharmaceuticals Incorporated (1.48%), Alnylam Pharmaceuticals, Inc. (2.42%), Biogen Inc. (2.18%), United Therapeutics Co. (4.45%), Neurocrine Biosciences, Inc. (4.54%), BioMarin Pharmaceutical Inc. (2.35%), Incyte Co. (3.36%), Exelixis, Inc. (7.20%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short Regeneron Pharmaceuticals stock? Short selling REGN is an investing strategy that aims to generate trading profit from Regeneron Pharmaceuticals as its price is falling. REGN shares are trading down $7.40 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Regeneron Pharmaceuticals? A short squeeze for Regeneron Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of REGN, which in turn drives the price of the stock up even further. How often is Regeneron Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including REGN, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies AMGN Short Interest Data GILD Short Interest Data VRTX Short Interest Data ALNY Short Interest Data BIIB Short Interest Data UTHR Short Interest Data NBIX Short Interest Data BMRN Short Interest Data INCY Short Interest Data EXEL Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:REGN) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy REGN Stock Free REGN Stock Alerts